These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8565286)

  • 21. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up.
    Christie JM; Healey CJ; Watson J; Wong VS; Duddridge M; Snowden N; Rosenberg WM; Fleming KA; Chapel H; Chapman RW
    Clin Exp Immunol; 1997 Oct; 110(1):4-8. PubMed ID: 9353141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic dysfunction in a population of antibody-deficient patients: prevalence, aetiology and outcome of PCR screening for hepatitis C and G viruses.
    O'Leary PF; Collingham K; Skidmore S; King J; Bennett CL; Williams PE; Pillay D; Thompson RA
    Vox Sang; 1999; 76(3):144-8. PubMed ID: 10341328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immunoglobulin and hepatitis C virus: the Scandinavian experience.
    Björkander J; Fasth A; Widell A
    Clin Ther; 1996; 18 Suppl B():73-82. PubMed ID: 8930444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intravenous immunoglobulin on clinical and immunological findings of patients with humoral immunodeficiency diseases.
    Ersoy F; Tezcan I; Sanal O
    Turk J Pediatr; 1992; 34(4):203-9. PubMed ID: 1306339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment.
    Rider NL; Kutac C; Hajjar J; Scalchunes C; Seeborg FO; Boyle M; Orange JS
    J Clin Immunol; 2017 Jul; 37(5):461-475. PubMed ID: 28536745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: evidence for HCV but not for GBV-C/HGV transmission.
    Berger A; Doerr HW; Scharrer I; Weber B
    J Med Virol; 1997 Sep; 53(1):25-30. PubMed ID: 9298728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transmission of hepatitis C virus in allografted patients: use of viral genotyping as an epidemiological marker.
    Gangneux JP; Traineau R; Tuveri R; Ravera N; Bureau C; Gluckman E; Benbunan M; Loiseau P
    Bone Marrow Transplant; 1996 Dec; 18(6):1131-3. PubMed ID: 8971383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and immunological features of common variable immunodeficiency in Mexican patients.
    Ramírez-Vargas N; Arablin-Oropeza SE; Mojica-Martínez D; Yamazaki-Nakashimada MA; de la Luz García-Cruz M; Terán-Juárez LM; Cortés-Grimaldo RM; Torres-Lozano C; Madrigal-Beas I; Ortega-Cisneros M; Vargas-Camaño ME; Staines-Boone T; Pietropaolo-Cienfuegos D; Berrón-Ruiz L; Espinosa-Rosales FJ; Guevara-Cruz M; Blancas-Galicia L
    Allergol Immunopathol (Madr); 2014; 42(3):235-40. PubMed ID: 23578780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Goals of therapy in antibody deficiency syndromes.
    Berger M
    J Allergy Clin Immunol; 1999 Nov; 104(5):911-3. PubMed ID: 10550731
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of pulmonary diseases in common variable immunodeficiency and X-linked agammaglobulinaemia.
    Aghamohammadi A; Allahverdi A; Abolhassani H; Moazzami K; Alizadeh H; Gharagozlou M; Kalantari N; Sajedi V; Shafiei A; Parvaneh N; Mohammadpour M; Karimi N; Sadaghiani MS; Rezaei N
    Respirology; 2010 Feb; 15(2):289-95. PubMed ID: 20051045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow up of patients with common variable immunodeficiency treated with intravenous immunoglobulin: reevaluation of intravenous immunoglobulin replacement therapy. IVIG therapy in CVID.
    Mushiake K; Motoyoshi F; Kondo N; Shimizu H; Orii T
    Biotherapy; 1993-1994; 7(2):101-7. PubMed ID: 7803189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin.
    Flora K; Schiele M; Benner K; Montanaro A; Johnston W; Whitham R; Press R
    Ann Allergy Asthma Immunol; 1996 Feb; 76(2):160-2. PubMed ID: 8595535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transmission rates of hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation.
    Lawlor E; Power J; Garson J; Yap P; Davidson F; Columb G; Smith D; Pomeroy L; O'Riordan J; Simmonds P; Tedder R
    Vox Sang; 1999; 76(3):138-43. PubMed ID: 10341327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of hepatitis B and C and relationship to liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic (JCRC), Kampala, Uganda.
    Baseke J; Musenero M; Mayanja-Kizza H
    Afr Health Sci; 2015 Jun; 15(2):322-7. PubMed ID: 26124775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of hepatitis C antibodies in patients with clotting disorders in Victoria. Relationship with other blood borne viruses and liver disease.
    Leslie DE; Rann S; Nicholson S; Fairley CK; Gust ID
    Med J Aust; 1992 Jun; 156(11):789-92. PubMed ID: 1321326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of hepatitis C in a chemically dependent population.
    Fingerhood MI; Jasinski DR; Sullivan JT
    Arch Intern Med; 1993 Sep; 153(17):2025-30. PubMed ID: 8357288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adult Common Variable Immunodeficiency.
    Dong J; Liang H; Wen D; Wang J
    Am J Med Sci; 2016 Mar; 351(3):239-43. PubMed ID: 26992251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.
    Lucas M; Lee M; Lortan J; Lopez-Granados E; Misbah S; Chapel H
    J Allergy Clin Immunol; 2010 Jun; 125(6):1354-1360.e4. PubMed ID: 20471071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency.
    Razvi S; Schneider L; Jonas MM; Cunningham-Rundles C
    Clin Immunol; 2001 Dec; 101(3):284-8. PubMed ID: 11726220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.